12:25 PM EST, 02/26/2025 (MT Newswires) -- Madrigal Pharmaceuticals ( MDGL ) shares advanced nearly 21% in recent Wednesday trading after the company released results for Q4 and new data on its Rezdiffra drug.

The company reported a Q4 net loss of $2.71 per diluted share on revenue of $103.3 million, topping market expectations.

The company also said patients with metabolic dysfunction-associated steatohepatitis treated with its Rezdiffra drug showed "marked reductions" in liver stiffness.

Price: 373.33, Change: +63.84, Percent Change: +20.63